-
Uncategorized3 weeks ago
BMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus
Plus, news about Gilead and West Pharma: 🏭Bristol Myers Squibb looks to Texas: The drugmaker is considering building a new pharma campus in Generation Park Management...
-
Uncategorized3 weeks ago
Lilly’s triple agonist shows bariatric surgery–like weight loss results
Lilly met analysts’ sky-high expectations with 28.3% weight loss over 80 weeks for the triple hormone receptor agonist retatrutide in a highly anticipated readout on Thursday.
-
Uncategorized3 weeks agoHow Florida hospitals won big in Medicaid funds (just in time)
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning and happy Thursday. Later this morning,...
-
Uncategorized3 weeks ago
Vaxart seeks shareholder support as battle over stock split brews
In September last year, a group of concerned stockholders raised alarm about Vaxart’s proposed reverse stock split, which the biotech was pushing for despite strong opposition...
-
Uncategorized3 weeks ago
Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling
A trifecta of newly inked tech partnerships—from Eli Lilly, Bristol Myers Squibb and Incyte—exemplify the increasingly central role that AI is playing in drug development.
-
Uncategorized3 weeks ago
Lilly’s triple agonist still leads among late-stage obesity assets
Lilly’s triple agonist still leads among late-stage obesity assets
-
Uncategorized3 weeks agoSTAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
Eli Lilly reported Thursday that in a late-stage trial, its next-generation obesity drug led to levels of weight loss approaching the effectiveness seen with bariatric surgery,...
-
Uncategorized3 weeks ago
Inside Germany’s biotech capital infrastructure and innovation engine
In this episode of Denatured, as part of our series of the European life science investment ecosystem, you’ll be hearing from Regina Hodits, managing director at...
-
Uncategorized3 weeks agoAre ‘AI co-scientist’ tools actually useful for scientists?
You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in...
-
Uncategorized3 weeks agoOpinion: STAT+: Dark times ahead at the FDA
I was at the annual American Society of Gene & Cell Therapy (ASGCT) meeting in Boston when news broke last week that Food and Drug Administration...
Amgen shores up Tavneos’ FDA defense with Duke data analysis
